Health Care Knowledge

  Abacavir/lamivudine is an FDA-approved prescription medication widely used for the treatment of human immunodeficiency virus (HIV) infection in adults. The abacavir lamivudine combination falls under the group of medicines known as nucleoside reverse transcriptase inhibitors (NRTIs), which help scale down the level of HIV in the blood. This medicinal product comes in tablet form and is taken once daily, with or without food. Common side effects due to abacavir/lamivudine include depression, trouble sleeping, and headache. Prior to initiating therapy with abacavir, screening for carriage of the HLA-B*5701 allele must be performed in any HIV-infected patient, irrespective of racial origin. Do not use Abacavir medicine if patients are known to carry the HLA-B*5701 allele. Posology and Method of Administration Therapy with Abacavir/lamivudine should be prescribed by a health specialist experienced in the management of HIV infection. The abacavir lamivudine tablet can be taken with or w

  Indication: Darunavir, co-administered with ritonavir (Darunavir/ritonavir), together with other existing antiretroviral agents, is authorized for treating human immunodeficiency virus (HIV-1) infection in adult and pediatric patients aged 3 years and older.  Standard Dosage in Adult Patients The darunavir tablet must be co-administered together with ritonavir to exert its therapeutic effect. Failure to correctly co-administer darunavir with ritonavir will result in plasma levels of darunavir that will be insufficient to achieve the required antiviral effect and will alter some drug interactions. Patients who have difficulty swallowing these tablets can use the 100 mg per mL darunavir oral suspension. Treatment-Naïve Adult Patients: The recommended oral dose of darunavir is 800 mg (1 × 800 mg tablet or 8 mL of  the oral suspension) taken with ritonavir 100 mg (1 × 100 mg tablet/capsule or 1.25 mL of an 80 mg per mL ritonavir oral solution) once daily and with meals. An 8 mL dose of

  Tegafur, gimeracil, and oteracil combination drugs are typically supplied under the brand name Furmecil. It is used along with the medicine cisplatin to treat advanced stomach cancer or unresectable cancer (gastric cancer that is difficult to remove by surgery) in adult patients. The combination of Tegafur Gimeracil Oteracil along with medication cisplatin has been considered a first-line treatment for unresectable cancer or cancer that come back after treatment. The standard therapy of Tegafur/Gimeracil/Oteracil with cisplatin is used with the intention in order to provide palliation (care given during terminal illness) and in order to prolong survival. Posology and Method of Administration Furmecil (Tegafur/Gimeracil/Oteracil) should only be prescribed by a qualified health specialist experienced in treating cancer patients with anti-neoplastic medicinal products.  The standard dose of Tegafur/Gimeracil/Oteracil when used in combination with cisplatin is 25 mg/m2 (as tegafur cont